|Bid||100.98 x 1300|
|Ask||101.15 x 1000|
|Day's Range||100.59 - 101.16|
|52 Week Range||81.66 - 101.32|
|Beta (3Y Monthly)||0.53|
|PE Ratio (TTM)||29.57|
|Forward Dividend & Yield||2.16 (2.16%)|
|1y Target Est||N/A|
DUBLIN, July 10, 2019 -- Medtronic plc (the “Company”) (NYSE:MDT) today announced the pricing terms of the previously announced cash tender offers by its wholly-owned indirect.
DUBLIN, July 10, 2019 -- Medtronic plc (the “Company”) (NYSE:MDT) today announced that, pursuant to the previously announced cash tender offers (collectively, the “Tender.
Medtronic plc (MDT) today announced two-year outcomes from the LATERAL clinical trial evaluating the use of its HeartWare™ HVAD™ System in patients who received the system via a less-invasive, thoracotomy implant approach. The HVAD System is a heart pump, called a left ventricular assist device (LVAD), that helps increase the amount of blood that circulates through the body in patients with advanced heart failure. Presented at the ASAIO (American Society for Artificial Internal Organs) 65th Annual Conference, the data showed that after two years of follow up, 95 percent of HVAD patients implanted via thoracotomy were free from disabling stroke (Modified Rankin Score, or mRS, greater than 3).
DUBLIN, July 02, 2019 -- Medtronic plc (the “Company”) (NYSE:MDT) today announced that its wholly-owned subsidiary Medtronic Global Holdings S.C.A. (“Medtronic Luxco”) has.
DUBLIN, June 25, 2019 -- Medtronic plc (NYSE:MDT) announced today that its wholly-owned subsidiary, Medtronic Global Holdings S.C.A. (“Medtronic Luxco”), has priced an offering.
DUBLIN, June 25, 2019 -- Medtronic plc (the “Company”) (NYSE:MDT) today announced the upsizing of the previously announced cash tender offer (the “Maximum Tender Offer”) by its.
DUBLIN - June 24, 2019 - Medtronic plc (the "Company") (NYSE:MDT) today announced the commencement of two cash tender offers by its wholly-owned indirect subsidiaries, Medtronic, Inc. ("Medtronic, ...
June 21, 2019 - The board of directors of Medtronic plc (MDT) today approved an 8 percent increase in its quarterly cash dividend, raising the quarterly amount to $0.54 per ordinary share. This would translate into an annual amount of $2.16 per ordinary share, or a dividend per share payout ratio of 41 percent of prior fiscal year non-GAAP diluted earnings per share (EPS). Today`s announcement marks the 42nd consecutive year of an increase in the dividend payment for Medtronic, a constituent of the S&P 500 Dividend Aristocrats index.
June 10, 2019 - Medtronic plc (MDT), the global leader in medical technology, today announced real-world data on its Guardian(TM) Connect continuous glucose monitoring (CGM) system and Sugar.IQ(TM) diabetes assistant app presented at the 79th Scientific Sessions of the American Diabetes Association (ADA) Annual Meeting in San Francisco. The data presented were recorded by users of the Guardian Connect system paired with Sugar.IQ diabetes assistant, a separate first-of-its-kind intelligent app that continually analyzes how an individual`s glucose levels respond to food intake, insulin dosages, daily routines and other factors1. The Sugar.IQ app combines data from the Guardian Connect system with artificial intelligence technology from Medtronic`s strategic partner, IBM® Watson Health, to detect important patterns and trends for people with diabetes and help them make more informed decisions on how to better manage glucose levels and stay within target range.
Four Year Partnership Made Public Today DUBLIN - June 10, 2019 - To enable upcoming regulatory filings, Medtronic plc (NYSE:MDT) today made public its partnership with KARL STORZ SE & Co. KG (Tuttlingen, ...
June 8, 2019 - Medtronic plc (MDT), the global leader in medical technology, today announced the enrollment of the first study participants in the company`s pivotal trial of its Bluetooth® enabled MiniMed(TM) 780G advanced hybrid closed loop (AHCL) system. This next-generation system is designed to automate the delivery of correction boluses when the user experiences, or is predicted to experience, prolonged high glucose levels based on their sensor readings. The trial will evaluate the safety of the MiniMed 780G system in participants with type 1 diabetes at home, at work, during exercise and other daily activities.
June 8, 2019 - Medtronic plc (MDT), the global leader in medical technology, today announced that it has initiated the company`s pivotal trial for its next-generation Guardian(TM) continuous glucose monitoring (CGM) sensor designed to improve accuracy and overall system performance, reduce sensor calibrations and enhance overall user experience. The multi-center, prospective trial will study the next-generation CGM sensor in up to 460 participants with type 1 or type 2 diabetes aged two to 80 years old over the course of seven days. Study participants will be randomly assigned to sensor wear location and testing days and times.
June 7, 2019 - Medtronic plc (MDT), the global leader in medical technology, services and solutions, and Tidepool, a 501(c)(3) nonprofit organization dedicated to making diabetes data more accessible, actionable and meaningful, have agreed to work together to create an interoperable automated insulin pump system. Medtronic will develop a future Bluetooth-enabled MiniMed(TM) pump that would be compatible with Tidepool Loop, a future FDA-regulated, open source automated insulin delivery app for iPhone® and Apple Watch® currently in development. "We think that Medtronic is making a very bold and important move here that shows tremendous courage and is the absolutely right thing for the diabetes community," said Howard Look, founder and CEO of Tidepool.
May 29, 2019 - Medtronic plc (MDT), the global leader in medical technology, today announced that it will participate in the Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11, 2019, in Rancho Palos Verdes, California. Omar Ishrak, Medtronic chairman and chief executive officer, will answer questions about the company beginning at 11:20 a.m. PDT (1:20 p.m. CDT). Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world`s largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world.
May 29, 2019 - Medtronic plc (MDT) today announced U.S. Food and Drug Administration (FDA) clearance and commercial launch for the SelectSite(TM) C304-HIS deflectable catheter system for use in procedures involving His-bundle pacing (HBP). The SelectSite C304-HIS deflectable catheter system features a deflectable, out-of-plane curve to reach the bundle of His and is designed to enable enhanced range maneuverability, fixation and implant success for a wider range of patient anatomies. The new catheter system facilitates placement of the Medtronic SelectSecure(TM) MRI SureScan(TM) Model 3830 cardiac pacing lead, the only pacing lead on the U.S. market approved for HBP.
May 28, 2019 - Medtronic plc (MDT), the global leader in medical technology, today announced it will participate in the Jefferies 2019 Global Healthcare Conference on Wednesday, June 5, 2019, in New York City. Mike Coyle, executive vice president and president of Medtronic`s Cardiac and Vascular group (CVG), will answer questions about the company beginning at 11:00 a.m. EDT (10:00 a.m. CDT). A live audio webcast of the session will be available on June 5, 2019, by clicking on the Investors Events link at http://investorrelations.medtronic.com. An archived audio file will be available for replay on the same webpage later in the day.
May 28, 2018 - Medtronic plc (MDT), the global leader in medical technology, today announced real-world clinical outcomes for the MiniMed(TM) 670G system, which is being used by more than 180,000 people today. The advanced algorithm in the MiniMed 670G system automates and personalizes the delivery of basal insulin 24 hours a day and is the only commercially available technology in the world that proactively drives increased Time in Range by consistently guiding to the target of 120 mg/dL throughout the day-the lowest range offered in an automated insulin pump system. See animation to understand how the MiniMed 670G system works.
May 24, 2019 - Medtronic plc (MDT), the global leader in medical technology, today announced that it will participate in the Bernstein 35th Annual Strategic Decisions Conference on Wednesday, May 29, 2019, in New York City. Omar Ishrak, chairman and chief executive officer of Medtronic, will make a presentation and will answer questions about the company beginning at 10:00 a.m. EDT (9:00 a.m. CDT). Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world`s largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world.
Q4 Revenue of $8.1 Billion, Flat as Reported and Grew 3.6% Organic Q4 GAAP Diluted EPS of $0.87; Q4 Non-GAAP Diluted EPS of $1.54 FY19 Revenue of $30.6 Billion Grew 2.0% Reported and 5.5% Organic FY19 ...
The data indicate that renal denervation (RDN) with the Medtronic Symplicity(TM) renal denervation system was associated with reduced occurrence of subclinical atrial fibrillation (AF) in a small subset of high-risk patients with hypertensive heart disease over a median follow-up period of more than two years. Results from the single-center, randomized, sham-controlled study were presented today during a Late-Breaking Clinical Trial session at the 2019 EuroPCR Annual Meeting in Paris. The investigator-led study funded by Medtronic randomized 80 patients to either the renal denervation procedure with the Symplicity renal denervation system or a fake "sham" procedure.
FDA Cleared and CE Marked, Telescope Enters Global Market with Design Innovations to Enable Smooth Delivery of Coronary Stents and Balloons DUBLIN - May 16, 2019 - Medtronic plc (NYSE:MDT), a global leader ...
Company to Proceed with Plans for Future Pivotal Study of New ICD System DUBLIN and SAN FRANCISCO - May 11, 2019 - Medtronic plc (NYSE:MDT) today announced findings from a pilot study of its investigational ...
May 10, 2019 - Three new studies show that patients who are medically indicated for implantable heart devices, including implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT), often do not receive needed therapy. The findings underscore gender and race treatment disparities, as well as a lack of referrals to physicians to implant the devices. Presented at Heart Rhythm 2019, the Heart Rhythm Society`s 40th Annual Scientific Sessions, the analyses were supported by Medtronic plc (MDT) and used Optum® Electronic Health Records (EHR) datasets and algorithms developed as part of the Medtronic GLIDE HF (GuideLine Indications Detected in EHR for HF) initiative.
May 10, 2019 - Medtronic plc (MDT) announced today that it will report financial results for its fourth quarter and fiscal year 2019 on Thursday, May 23, 2019. The news release will include summary financial information for the company`s fourth quarter and fiscal year 2019, which ended on Friday, April 26, 2019. Medtronic will host a webcast at 7:00 a.m. CDT to discuss financial results for its fourth quarter and full fiscal year 2019.
May 9, 2019 - Medtronic plc (MDT), a global leader in medical technology, today announced that it has entered into a definitive agreement pursuant to which it will acquire Titan Spine, a privately-held titanium spine interbody implant and surface technology company. The boards of directors of both companies have unanimously approved the transaction. Terms of the transaction are not being disclosed.